New hope for Hard-to-Treat colorectal cancer: experimental drug combo enters human trials
Disease control
By invitation only
This study tests a new oral drug called XS-03 combined with standard chemotherapy and a targeted antibody (bevacizumab) in 102 people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if the combination is safe and shrinks tumors better than current tr…
Phase 1/2 • Sponsor: NovaOnco Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC